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S U M M A R Y
Background: This analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) reports
on 24 784 isolates collected from integumentary culture sources between 2004 and 2009.
Methods: Minimum inhibitory concentrations (MICs) and susceptibility were determined according to
the Clinical and Laboratory Standards Institute guidelines (US Food and Drug Administration
breakpoints applied against tigecycline).
Results: All methicillin-resistant Staphylococcus aureus were susceptible to tigecycline, linezolid, and
vancomycin. MIC90s for tigecycline against Enterococcus faecalis and Enterococcus faecium ranged
between 0.12 mg/l and 0.25 mg/l. Resistance to the carbapenems and tigecycline was low among the
Enterobacteriaceae, with resistance at 2.0% between 2004 and 2009 for tigecycline against Klebsiella
pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter spp, and Serratia marcescens, for imipenem
against E. coli and Enterobacter spp, and for meropenem against E. coli, Enterobacter spp, and S. marcescens.
Against the Acinetobacter baumannii collected in 2009, resistance to amikacin, ceftazidime, levoﬂoxacin,
meropenem, and piperacillin–tazobactam was >30%; between 2004 and 2009 resistance to minocycline
varied between 1.4% and 4.8%, and tigecycline MIC90s were 2 mg/l. Against the Pseudomonas aeruginosa
collected, MIC90s were greater than the susceptibility breakpoint for cefepime, ceftazidime, imipenem,
levoﬂoxacin, and meropenem.
Conclusions: The problem of antimicrobial resistance is demonstrated by the data presented. T.E.S.T.
continues to provide valuable information on antimicrobial resistance globally.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Complicated skin and skin structure infections (cSSSI) are
commonly caused by Gram-positive bacteria and in particular
Staphylococcus aureus.1 However, the etiology can become more
complex in hospital-associated infections and in patients with co-
morbidities where Gram-negative organisms are frequently
involved.1,2 The continuing development of antimicrobial resis-
tance makes the appropriate treatment of cSSSI difﬁcult and has
resulted in an unmet clinical need in the treatment of some
hospital infections.
Unfortunately, there are few new antimicrobial agents in
development, with the pipeline of agents active against Gram-
negative organisms particularly lean.3 Tigecycline, which was
initially approved by the US Food and Drug Administration
(FDA) in 2005, is a novel glycylcycline antimicrobial with an
expanded broad-spectrum of activity, licensed for the treatment* Corresponding author. Tel.: +1 570 702 8132; fax: +1 570 702 8131.
E-mail address: hnamdari@clinmicro.com (H. Namdari).
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doi:10.1016/j.ijid.2011.09.021of cSSSI, complicated intra-abdominal infections (cIAI), and
community-acquired bacterial pneumonia. The Tigecycline
Evaluation and Surveillance Trial (T.E.S.T.) is a global multicen-
ter surveillance study designed to assess the in vitro activity of
tigecycline and comparators against a range of clinically
important Gram-positive and Gram-negative pathogens. This
paper will report on isolates collected globally from integumen-
tary culture sources between 2004 and 2009.
2. Methods
Centers involved in T.E.S.T. were requested to submit 65 Gram-
positive and 135 Gram-negative organisms each year. Overall, 543
centers in 58 countries submitted isolates from integumentary
sources between 2004 and 2009 (not all centers submitted in all
years). Isolates were consecutive and clinically signiﬁcant (as
determined by local criteria). Isolates requested in the protocol
included: Enterococcus spp (n = 15), S. aureus (n = 25), Acinetobacter
spp (n = 15), Escherichia coli (n = 25), Enterobacter spp (n = 25),
Pseudomonas aeruginosa (n = 20), Serratia spp (n = 10), and Klebsi-
ella spp (n = 25). A single isolate per patient was accepted. Theses. Published by Elsevier Ltd. All rights reserved.
Table 1
Global rates of resistant phenotypes of Gram-positive and Gram-negative organisms collected from integumentary sources as part of T.E.S.T. between 2004 and 2009
MRSA Vancomycin-
resistant
E. faecalis
Vancomycin-
resistant
E. faecium
ESBL-
producing
K. pneumoniae
ESBL-
producing
K. oxytoca
ESBL-
producing
E. coli
n % n % n % n % n % n %
2004 330/744 44.4 3/215 1.4 23/51 45.1 20/161 12.4 4/77 5.2 17/249 6.8
2005 478/944 50.6 18/222 8.1 35/55 63.6 33/198 16.7 1/74 1.4 14/281 5.0
2006 461/1084 42.5 9/347 2.6 53/95 55.8 60/289 20.8 7/111 6.3 42/429 9.8
2007 749/1665 45.0 9/463 1.9 48/107 44.9 69/394 17.5 3/158 1.9 54/584 9.2
2008 381/1120 34.0 3/317 0.9 30/94 31.9 85/345 24.6 8/123 6.5 76/455 16.7
2009 422/1254 33.7 13/351 3.7 22/116 19.0 94/384 24.5 3/157 1.9 87/506 17.2
All years 2821/6811 41.4 55/1915 2.9 211/518 40.7 361/1771 20.4 26/700 3.7 290/2504 11.6
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MRSA, methicillin-resistant Staphylococcus aureus; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; K.
pneumoniae, Klebsiella pneumoniae; K. oxytoca, Klebsiella oxytoca; E. coli, Escherichia coli; ESBL, extended-spectrum b-lactamase.
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medical history, previous antimicrobial use, sex, and age.
Culture source information was requested for each isolate.
Isolates were included in this study where their culture source was
listed as integumentary; this included burns, decubitus ulcers,
skin, and wounds.
Minimum inhibitory concentrations (MICs) were determined
at individual centers using broth microdilution methodology
(Sensititre1 plates, TREK Diagnostic Systems, West Sussex, UK; or
MicroScan1 panels, Siemens, Sacramento, CA, USA), according to
the guidelines published by the Clinical and Laboratory Standards
Institute (CLSI).4 Gram-positive isolates were tested against
amoxicillin–clavulanate, ampicillin, ceftriaxone, imipenem, levo-
ﬂoxacin, linezolid, meropenem, minocycline, penicillin, pipera-
cillin–tazobactam, tigecycline, and vancomycin. Gram-negative
isolates were tested against amikacin, amoxicillin–clavulanate,
ampicillin, cefepime, ceftazidime, ceftriaxone, imipenem, levo-
ﬂoxacin, meropenem, minocycline, piperacillin–tazobactam, and
tigecycline.
A switch from imipenem to meropenem occurred in 2006
because of inadequate imipenem stability on the testing panels.
Because of the availability of imipenem and meropenem on the
testing panels, a switch was also made from MicroScan panels to
Sensititre plates, with all imipenem testing carried out on
MicroScan panels and all meropenem testing carried out on
Sensititre plates. Laboratories International for Microbiology
Studies, a division of International Health Management Associates,
Inc. (IHMA, Schaumburg, IL, USA) organized isolate collection and
transport, and coordinated the conﬁrmation of isolate identiﬁca-
tion and the development and management of a centralized
database.
Quality control strains used in the testing of Enterococcus spp
and S. aureus were S. aureus ATCC 29213 and Enterococcus faecalis
ATCC 29212. Against Acinetobacter spp, P. aeruginosa, and the
Enterobacteriaceae, E. coli ATCC 25922 and P. aeruginosa ATCC
27853 were used.Table 2
Regional rates of resistant phenotypes of Gram-positive and Gram-negative organisms
MRSA E
p
n % n
Africa 37/106 34.9 
Asia-Paciﬁc 148/383 38.6 
Europe 526/2217 23.7 1
Latin America 209/453 46.1 
Middle East 36/191 18.8 
North America 1865/3461 53.9 
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MRSA, methicillin-resistant Stap
a Vancomycin-resistant Enterococcus not presented due to low number values in somIsolates of E. coli and Klebsiella spp were tested for extended-
spectrum b-lactamase (ESBL) production according to the CLSI
guidelines5 using cefotaxime (30 mg/l), cefotaxime–clavulanic
acid (30/10 mg/l), ceftazidime (30 mg/l), and ceftazidime–clavu-
lanic acid (30/10 mg/l) discs. Discs were manufactured by Oxoid,
Inc. (Ogdensburg, NY, USA) and the Mueller–Hinton agar used in
testing by Remel, Inc. (Lenexa, KS, USA). The quality control
strains used were Klebsiella pneumoniae ATCC 700603 (ESBL-
positive) and E. coli ATCC 25922 (ESBL-negative), and P.
aeruginosa (ATCC 27853) for quality control of the ceftazidime
and cefotaxime discs.
Antimicrobial susceptibility was determined according to CLSI
interpretive criteria.5 For the carbapenems against the Enterobac-
teriaceae, the June 2010 updated criteria were applied.6 For
tigecycline, the FDA approved breakpoints, as provided in the
package insert, were used.7
3. Results
3.1. Gram-positive organisms
Between 2004 and 2009, 6811 isolates of S. aureus were
submitted from integumentary sources globally, of which 41.4%
were identiﬁed as methicillin-resistant S. aureus (MRSA) (Table 1).
The highest percentage of MRSA was collected in 2005 (50.6%), and
from the pooled collection of MRSA (2004–2009) rates varied from
18.8% in the Middle East to 53.9% in North America (Table 2). No
isolates of MRSA were resistant to linezolid, tigecycline, or
vancomycin, with the MICs for all isolates at or below the
susceptibility breakpoint (Table 3).
Of the 1915 isolates of E. faecalis submitted between 2004 and
2009, 2.9% were vancomycin-resistant (Table 1). Globally, resistance
to minocycline among E. faecalis increased between 2004 and 2009,
from 14.0% to 51.0% (Table 3). Four isolates of linezolid-resistant E.
faecalis were identiﬁed, three in 2005 and one in 2009. Two of the
isolates from 2005 were vancomycin-resistant; the remaining 2005 collected from integumentary sources as part of T.E.S.T. (pooled 2004–2009)a
SBL-producing Klebsiella
neumoniae
ESBL-producing Escherichia coli
 % n %
18/47 38.3 3/40 7.5
20/79 25.3 21/96 21.9
29/591 21.8 141/896 15.7
98/228 43.0 74/271 27.3
18/66 27.3 15/84 17.9
78/760 10.3 36/1117 3.2
hylococcus aureus; ESBL, extended-spectrum b-lactamase.
e regions.
Table 3
In vitro susceptibility of Gram-positive organisms collected from integumentary sources as part of T.E.S.T. between 2004 and 2009
2004 2005 2006 2007 2008 2009
MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R
MSSA n=414 n=466 n=623 n=916 n=739 n=832
Levoﬂoxacin 0.5 3.1 0.5 7.5 0.5 4.3 1 7.0 0.5 5.1 1 6.0
Linezolid 4 0.0 2 0.0 4 0.0 4 0.0 2 0.0 4 0.0
Minocycline 0.25 0.0 0.25 0.0 0.25 0.0 0.25 0.1 0.5 0.0 0.5 1.1
Penicillin 16 86.2 16 82.6 16 84.1 16 84.6 16 85.4 16 81.9
Tigecyclinea 0.12 (0) 0.12 (0) 0.25 (0) 0.25 (0) 0.25 (0) 0.25 (0)
Vancomycin 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0
MRSA n=330 n=478 n=461 n=749 n=381 n=422
Levoﬂoxacin 64 70.9 32 63.4 64 66.6 32 60.3 32 72.2 32 76.8
Linezolid 2 0.0 2 0.0 4 0.0 2 0.0 2 0.0 2 0.0
Minocycline 0.5 0.0 0.5 0.0 0.5 0.0 0.5 0.3 4 3.1 4 4.7
Tigecyclinea 0.25 (0) 0.25 (0) 0.25 (0) 0.25 (0) 0.25 (0) 0.5 (0)
Vancomycin 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0 1 0.0
E. faecalis n=215 (204/11) n=222 (211/11) n=347 (196/151) n=463 (6/457) n=317 (0/317) n=351 (0/351)
AMC 1 - 1 - 1 - 1 - 1 - 1 -
Ampicillin 1 0.0 1 0.0 1 0.0 1 0.0 2 0.3 2 0.9
Imipenem 1 - 2 - 8 - - - - - - -
Levoﬂoxacin 64 34.4 64 41.0 64 34.3 64 32.8 64 35.6 64 31.6
Linezolid 2 0.0 2 1.4b 2 0.0 2 0.0 2 0.0 2 0.3b
Meropenem - - - - 8 - 8 - 8 - 8 -
Minocycline 16 14.0 16 10.8 16 14.7 16 19.2 16 40.1 16 51.0
Penicillin 4 0.0 4 0.0 4 0.3 4 0.2 4 0.3 4 2.0
TZP 4 - 4 - 4 - 8 - 8 - 8 -
Tigecyclinea 0.12 (0) 0.12 (2) 0.12 (1) 0.25 (0) 0.25 (1) 0.25 (2)
Vancomycin 2 1.4 2 8.1 2 2.6 2 1.9 2 0.9 2 3.7
E. faecium n=51 (47/4) n=55 (52/3) n=95 (50/45) n=107 (4/103) n=94 (0/94) n=116 (0/116)
AMC 16 - 16 - 16 - 16 - 16 - 16 -
Ampicillin 32 82.4 32 87.3 32 82.1 32 81.3 32 80.9 32 69.0
Imipenem 32 - 32 - 32 - - - - - - -
Levoﬂoxacin 64 78.4 64 83.6 64 85.3 64 80.4 64 78.7 64 78.4
Linezolid 2 2.0 2 0.0 2 0.0 2 0.9 2 0.0 2 0.0
Meropenem - - - - 32 - 32 - 32 - 32 -
Minocycline 16 17.6 8 5.5 8 6.3 16 13.1 16 25.5 16 20.7
Penicillin 16 82.4 16 87.3 16 83.2 16 82.2 16 80.9 16 73.3
TZP 32 - 32 - 32 - 32 - 32 - 32 -
Tigecyclinea 0.12 (0) 0.12 (0) 0.12 (0) 0.12 (0) 0.25 (2) 0.25 (1)
Vancomycin 64 45.1 64 63.6 64 55.8 64 44.9 64 31.9 64 19.0
T.E.S.T., Tigecycline Evaluation and Surveillance Trial; MIC90, minimum inhibitory concentration required to inhibit the growth of 90% of isolates (mg/l); R, resistant; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA,
methicillin-resistant Staphylococcus aureus; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; AMC, amoxicillin–clavulanate; TZP, piperacillin–tazobactam.
Number values given in parentheses refer to the number of isolates tested against imipenem and meropenem, respectively. Data not presented when n  20.
a No resistance breakpoint available, number of isolates above the susceptibility breakpoint given in parentheses.
b MIC range 0.5mg/l to 16mg/l in 2005, and 0.5mg/l to 8mg/l in 2009.
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2009. The agents with the lowest MIC90s against E. faecalis in this
study were amoxicillin–clavulanate (MIC90 1 mg/l), ampicillin
(MIC90 2 mg/l), and tigecycline (0.25 mg/l).
A total of 518 isolates of Enterococcus faecium were submitted
from integumentary sources, of which 40.7% were vancomycin-
resistant (Table 1). Against the E. faecium collected, resistance was
highest to ampicillin, levoﬂoxacin, and penicillin (Table 3). The
lowest MIC90s were for linezolid (MIC90 2 mg/l) and tigecycline
(MIC90 0.25 mg/l).
3.2. Gram-negative organisms
Between 2004 and 2009, a total of 1771 isolates of K.
pneumoniae were submitted from integumentary sources, with
20.4% identiﬁed as ESBL producers (Table 1). The highest
percentages of isolates identiﬁed as ESBL producers were collected
in 2008 (24.6%) and 2009 (24.5%). Rates of ESBL production varied
between 10.3% of isolates in North America to 43.0% of isolates in
Latin America (Table 2). Higher rates of resistance to the
antimicrobials in the panel were reported among isolates of K.
pneumoniae for the later years of this study when compared with
the results for 2004 (Table 4). The agents with the lowest MIC90s
across the 6 years were the carbapenems and tigecycline.
Small numbers of the 700 isolates of Klebsiella oxytoca were
identiﬁed as ESBL producers (3.7%) (Table 1). No antimicrobial
agent was universally active against all isolates of K. oxytoca; small
numbers of isolates (<5% in any year) with resistance to amikacin,
cefepime, imipenem, meropenem, and tigecycline were collected
(Table 4). Increasing percentages of resistant isolates were noted
for minocycline, although the rates in 2009 were lower than 2008
(Table 4). MIC90s of 1 mg/l were reported for tigecycline in all
years, imipenem and meropenem in all years tested, cefepime in
2004 and 2005, and levoﬂoxacin in 2004, 2005, 2006, and 2007.
Of the 2504 isolates of E. coli collected between 2004 and 2009,
a total of 11.6% were identiﬁed as ESBL producers (Table 1). The
rates of ESBL-producing E. coli increased markedly over the course
of the study, from 6.8% in 2004 to 17.2% in 2009. Rates were highly
variable among the regions, ranging from 3.2% in North America to
27.3% in Latin America (Table 2). Increases of >10% in resistance
between 2004 and 2009 were noted for ampicillin, ceftriaxone,
levoﬂoxacin, and minocycline (Table 4). No isolates with resistance
to tigecycline were identiﬁed, and the MIC90 for tigecycline
remained constant (within one doubling dilution).
Between 2004 and 2009, 3589 isolates of Enterobacter spp were
submitted from integumentary sources. Increasing rates of
ceftriaxone and minocycline resistance (>10% increase between
2004 and 2009) were noted among isolates of Enterobacter spp
(Table 4). The agents with the lowest rates of resistance across the
6 years of study were amikacin, the carbapenems, and tigecycline
(<2% resistance with the exception of amikacin in 2009, 3.2%).
Overall, 1381 isolates of Serratia marcescens were collected
between 2004 and 2009 (Table 4). Resistance to minocycline
increased from 2.9% in 2004 to 12.7% in 2009. Resistance was low
(<5%) to all other antimicrobials in the panel, with the exception of
ceftriaxone (between 8.1% and 13.3%).
Resistance among isolates of Acinetobacter baumannii
(n = 2145) to amikacin and piperacillin–tazobactam increased
markedly over time (Table 4). The agents with the lowest MIC90s
against A. baumannii were imipenem and minocycline (MIC90s
8 mg/l) and tigecycline (MIC90s 2 mg/l).
A total of 3450 P. aeruginosa isolates were collected from
integumentary sources (Table 4). Over the course of the study,
MIC90s were greater than the susceptibility breakpoint for cefepime,
ceftazidime, imipenem, levoﬂoxacin, and meropenem. The MIC90
for piperacillin–tazobactam was equal to the susceptibilitybreakpoint from 2004 to 2006 and exceeded it from 2007 onwards.
The largest increases in resistance between 2004 and 2009 were for
piperacillin–tazobactam (9.8% to 18.3%) and ceftazidime (11.4% to
20.7%). Tigecycline was not active against P.aeruginosa (MIC90 16 to
32 mg/l).
4. Discussion
This study reports rates of antimicrobial resistance among
24 784 Gram-positive and Gram-negative isolates collected from
integumentary culture sources between 2004 and 2009 as part of
the T.E.S.T. study. The global percentages of MRSA reported by this
study varied from 33.7% in 2009 to 50.6% in 2005, which suggests a
fall in MRSA rates globally. Regional number values are too small to
indicate which geographical regions contributed to this fall;
however, recent reports from the USA and Europe have suggested
that MRSA rates may be leveling off or decreasing.8–11
Despite the recent emergence among S. aureus of a transferable
resistance mechanism to linezolid,12 as reported by T.E.S.T. for S.
aureus from all culture sources,13 and by others,14 all isolates,
irrespective of resistance phenotype, were susceptible to linezolid.
All isolates were also susceptible to tigecycline and vancomycin.
Vancomycin MICs among isolates of MRSA ranged from 0.12 mg/l
to 2 mg/l.
As shown by the results of this study, the in vitro activity of
linezolid against enterococci remains reliable, with rare cases of
linezolid resistance. Linezolid-resistant enterococci have been
reported by other researchers.15 Tigecycline also had reliable
activity against both E. faecalis and E. faecium from integumentary
sources, with low MIC90s between 2004 and 2009. These results are
similar to those reported by Bradford et al.16 for isolates collected
from patients enrolled in phase 3 clinical trials for the treatment of
cSSSI. It is notable that minocycline resistance among isolates of E.
faecalis increased between 2004 and 2009. Reasons for increasing
minocycline resistance are unclear. Links between antimicrobial
use and resistance have been made (e.g., Lai et al.17) and it is
possible this was a factor; however, no data on antimicrobial use
are available as part of this study. Tigecycline is unaffected by
tetracycline resistance mechanisms18,19; however, Chen et al.20
have reported decreased tigecycline susceptibility after tigecycline
usage. No change in tigecycline activity among the enterococci was
noted over the course of this study.
Although the focus in recent years has been on the importance
of Gram-positive organisms, Gram-negative organisms present
clinicians with considerable challenges, which are now being
recognized. Among the isolates of Enterobacteriaceae, A. baumannii,
and P. aeruginosa reported here, resistance rates were high to many
of the antimicrobials in the panel. Increases in rates of resistance
between 2004 and 2009 were noted for a number of antimicrobial/
organism combinations, with resistance to minocycline increasing
among isolates of Enterobacteriaceae.
Rates of ESBL production among K. pneumoniae and E. coli were
20.4% and 11.6%, respectively between 2004 and 2009, with the
highest rates seen in the Latin American region (43.0% and 27.3%,
respectively). In an analysis of the entire T.E.S.T. dataset, Garrison
et al.13 observed a steady increase in the rates of ESBL production,
which is not as apparent within this subset (although rates in 2008
and 2009 were higher than those from 2004 and 2005). The agents
with the lowest MIC90s against the Enterobacteriaceae varied by
species; tigecycline and the carbapenems had consistently low
MIC90s, and in addition, MIC90s were low for levoﬂoxacin against K.
oxytoca (although they increased from 0.25 mg/l in 2004–2005 to
4 mg/l in 2008–2009) and amikacin against Enterobacter spp.
Carbapenem-resistant Enterobacteriaceae have emerged glob-
ally and their presence limits treatment options.21 Discussion on
changing rates of carbapenem resistance in the T.E.S.T. program is
Table 4
In vitro susceptibility of Gram-negative organisms collected from integumentary sources as part of T.E.S.T. between 2004 and 2009
2004 2005 2006 2007 2008 2009
MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R MIC90 % R
K. pneumoniae n=161 (158/3) n=198 (188/10) n=289 (174/115) n=394 (12/382) n=345 (0/345) n=384 (0/384)
Amikacin 4 1.2 8 2.0 16 2.8 8 2.3 16 7.5 16 4.7
AMC 16 9.9 32 16.7 32 20.1 64 18.3 64 24.3 64 23.7
Cefepime 8 3.7 4 7.1 32 12.8 32 11.4 64 14.2 64 18.0
Ceftriaxone 32 16.8 16 18.7 128 29.1 128 26.1 128 32.8 128 35.9
Imipenem 0.5 0.6 0.5 0.5 0.5 3.4 - - - - - -
Levoﬂoxacin 2 7.5 8 14.1 16 18.7 16 19.8 16 22.3 16 24.7
Meropenem - - - - 0.5 5.2 0.25 5.0 0.12 3.2 0.5 6.3
Minocycline 16 10.6 16 14.1 16 12.1 16 15.5 32 21.4 32 20.6
TZP 32 5.0 256 12.6 256 14.2 128 11.4 256 20.3 256 16.9
Tigecycline 2 0.0 2 0.5 2 0.0 2 0.5 2 0.3 2 0.5
K. oxytoca n=77 (76/1) n=74 (72/2) n=111 (78/33) n=158 (3/155) n=123 (0/123) n=157 (0/157)
Amikacin 4 0.0 4 0.0 4 1.8 4 0.6 2 0.8 4 0.6
AMC 16 5.2 8 6.8 16 9.9 32 15.2 32 13.8 16 9.6
Cefepime 1 2.6 0.5 0.0 2 3.6 2 1.3 2 1.6 2 1.9
Ceftriaxone 4 11.7 2 5.4 16 16.2 8 12.7 16 17.1 8 15.9
Imipenem 0.5 0.0 0.5 0.0 0.5 3.8 - - - - - -
Levoﬂoxacin 0.25 0.0 0.25 1.4 1 6.3 1 4.4 4 8.1 4 5.1
Meropenem - - - - 0.12 0.0 0.12 2.6 0.06 1.6 0.06 0.0
Minocycline 4 1.3 4 2.7 4 4.5 4 5.1 8 7.3 8 4.5
TZP 128 10.4 8 6.8 64 9.9 128 10.1 256 14.6 128 10.2
Tigecycline 1 0.0 1 0.0 0.5 1.8 1 0.0 1 0.0 1 0.0
E. coli n=249 (247/2) n=281 (276/5) n=429 (244/185) n=584 (10/574) n=455 (0/455) n=506 (0/506)
Amikacin 8 0.8 4 0.4 8 0.5 8 0.9 8 2.4 8 1.6
AMC 32 13.3 32 15.7 32 16.8 32 15.4 32 18.9 32 17.0
Ampicillin 64 57.8 64 59.8 64 59.4 64 63.2 64 67.7 64 69.6
Cefepime 1 2.4 1 2.5 8 6.5 8 5.7 16 9.9 16 9.7
Ceftriaxone 4 10.4 4 11.0 64 16.3 128 16.3 128 24.6 128 24.1
Imipenem 0.5 0.4 0.5 0.0 0.5 2.0 - - - - - -
Levoﬂoxacin 16 21.7 16 24.9 16 30.5 16 34.6 16 37.1 16 36.6
Meropenem - - - - 0.12 0.0 0.06 0.5 0.06 0.9 0.06 1.0
Minocycline 8 7.2 8 4.6 16 10.5 16 12.7 16 17.1 16 21.3
TZP 4 2.8 4 1.8 16 4.9 16 3.6 32 4.2 32 5.7
Tigecycline 0.25 0.0 0.25 0.0 0.5 0.0 0.5 0.0 0.5 0.0 0.5 0.0
Enterobacter spp n=362 (347/15) n=441 (428/13) n=589 (344/245) n=803 (17/786) n=677 (0/677) n=717 (0/717)
Amikacin 2 0.0 4 1.6 4 1.2 4 1.5 4 1.9 4 3.2
Cefepime 2 0.6 4 2.7 8 5.3 4 3.5 4 3.4 8 5.0
Ceftriaxone 32 19.3 64 25.2 64 28.2 64 27.0 64 32.9 128 37.4
Imipenem 1 0.0 1 1.6 1 0.3 - - - - - -
Levoﬂoxacin 0.5 4.4 4 9.1 4 8.8 2 7.7 4 7.8 8 10.5
Meropenem - - - - 0.25 1.2 0.25 1.0 0.25 1.9 0.25 1.5
Minocycline 4 4.7 8 5.7 8 7.5 16 10.2 16 12.0 16 16.0
TZP 32 3.9 64 6.1 128 10.7 64 8.3 128 10.8 128 12.1
Tigecycline 1 1.9 1 1.4 1 0.5 1 1.1 2 1.2 2 1.0
S. marcescens n=136 (130/6) n=176 (164/12) n=216 (132/84) n=335 (10/325) n=202 (0/202) n=316 (0/316)
Amikacin 4 0.7 4 0.0 4 0.9 8 2.4 4 3.5 4 1.3
Cefepime 0.5 0.7 1 1.1 1 1.4 1 1.5 2 1.5 2 3.2
Ceftriaxone 2 8.1 2 9.1 2 9.7 4 11.3 4 12.9 8 13.3
Imipenem 1 1.5 1 0.0 1 3.8 - - - - - -
Levoﬂoxacin 1 0.7 1 1.1 1 1.9 1 2.4 2 4.5 2 4.1
Meropenem - - - - 0.25 0.0 0.12 0.9 0.12 1.0 0.12 1.3
Minocycline 4 2.9 4 0.6 4 1.4 8 4.2 16 10.9 16 12.7
TZP 4 0.7 4 1.7 16 1.9 8 2.1 8 2.5 8 0.9
Tigecycline 1 0.0 2 0.6 2 0.5 2 0.9 2 0.0 2 0.6
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2006, as with the introduction of the revised carbapenem
breakpoints in 2009,6 the activity of imipenem and meropenem
are not comparable. The most recent data in this study are
available for meropenem, with the highest rate of resistance
measured among isolates of K. pneumoniae (6.3%). Rates among
other members of the Enterobacteriaceae ranged from 0.0% among
K. oxytoca to 1.5% among Enterobacter spp. Continued surveillance
is important to monitor changing and emerging trends in
carbapenem susceptibility.
A. baumannii and P. aeruginosa are uncommon pathogens;
however, their intrinsic resistance to many antimicrobials makes
them particularly problematic to treat. Among the A. baumannii
submitted from integumentary sources in this study, resistance to
many of the antimicrobials was greater than 30% in 2009, and the
agents with the lowest MIC90s were minocycline and tigecycline.
Minocycline is considered an unconventional choice in the
treatment of A. baumannii infections; however, recently there
has been renewed interest in its clinical use.22 Tigecycline is active
against A. baumannii in vitro; however, clinical evidence is
lacking,23 and there are no accepted susceptibility breakpoints.
Among the P. aeruginosa collected, resistance to the antipseudo-
monal b-lactams, piperacillin–tazobactam and ceftazidime, in-
creased between 2004 and 2009, with resistance at 18.3% and
20.7%, respectively in 2009. Jones et al.24 recently reported a trend
of decreasing susceptibility to piperacillin–tazobactam between
1997 and 2007 in Asia-Paciﬁc, North America, and Europe.
As with the Enterobacteriaceae, commenting on changing rates of
carbapenem resistance among A. baumannii and P. aeruginosa is
problematic given the switch from imipenem to meropenem in
2006. Approximately one third of A. baumannii isolates and 14% of P.
aeruginosa were resistant to meropenem in 2009. The carbapenems
are frequently used as an indicator of multidrug resistance in these
species and the rates of resistance reported here, particularly in the
case of A. baumannii, indicate the limited treatment options available
for some infections caused by these organisms.
There are few global antimicrobial surveillance studies
currently in operation, and these results from T.E.S.T. demonstrate
the value of such global datasets. However, there are limitations to
this study that should be mentioned. T.E.S.T. has now been running
for 6 years and 166 of the 543 centers (30.6%) that contributed
isolates from integumentary sources did so in three or more of the
6 years. Antimicrobial resistance is known to vary among, and
within, hospitals, and therefore some of the year on year changes
may be a result of these changes in centers. Also, 40.9% (222/543)
of the T.E.S.T. centers are based in the USA, which is likely to result
in an overrepresentation of North America in the global data.
In conclusion, these data highlight the problem of antimicrobial
resistance among Gram-positive and Gram-negative organisms
isolated from integumentary culture sources. Tigecycline, line-
zolid, and vancomycin showed consistent activity against the
Gram-positive organisms studied, including MRSA. Against the
Gram-negative collection, antimicrobial resistance was particular-
ly problematic, and in the case of P. aeruginosa, no antimicrobial
agents in the T.E.S.T. panel demonstrated reliable activity. Against
the Enterobacteriaceae, the carbapenems and tigecycline demon-
strated consistent antimicrobial activity irrespective of the year of
collection, and the agents with the lowest MIC90s against A.
baumannii were minocycline and tigecycline.
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